SILLAJEN, INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3,120 KRW | -9.57% |
|
-14.52% | -48.26% |
| Sales 2022 | 5.01B 3.64M | Sales 2023 | 3.94B 2.86M | Capitalization | 620B 450M |
|---|---|---|---|---|---|
| Net income 2022 | -24.59B -17.85M | Net income 2023 | -20.37B -14.79M | EV / Sales 2022 | 131 x |
| Net cash position 2022 | 59.87B 43.47M | Net cash position 2023 | 39.6B 28.75M | EV / Sales 2023 | 147 x |
| P/E ratio 2022 |
-29.1
x | P/E ratio 2023 |
-30.4
x | Employees | 37 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 72.42% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| 1 day | -9.57% | ||
| 1 week | -14.52% | ||
| Current month | -14.52% | ||
| 1 month | -24.55% | ||
| 3 months | -34.59% | ||
| 6 months | -45.83% | ||
| Current year | -48.26% |
1 week
2 980.00
3 640.00
1 month
2 980.004 305.00
Current year
2 980.006 620.00
1 year
2 980.007 260.00
3 years
2 980.0016 550.00
5 years
2 980.0051 500.00
10 years
2 980.00152 300.00
| Managers | Title | Age | Since |
|---|---|---|---|
Eun-Sang Moon
CEO | Chief Executive Officer | 59 | 14-01-31 |
Kyung-Mi Yang
CTO | Chief Tech/Sci/R&D Officer | 58 | - |
Ji-Won Choi
CTO | Chief Tech/Sci/R&D Officer | 57 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Eun-Sang Moon
CEO | Chief Executive Officer | 59 | 14-01-31 |
Yong-Jae Jang
BRD | Director/Board Member | 57 | - |
Myung-Seok Song
BRD | Director/Board Member | 57 | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-07-05 | 3,120 | -9.57% | 5,161,648 |
| 24-07-04 | 3,450 | -0.14% | 376,319 |
| 24-07-03 | 3,455 | -1.29% | 482,558 |
| 24-07-02 | 3,500 | -3.85% | 466,799 |
| 24-07-01 | 3,640 | -0.27% | 382,957 |
End-of-day quote Korea S.E., July 04, 2024
More quotes
SillaJen Inc is a Korea-based company primarily engaged in the research and development of oncolytic virus immunotherapeutics. The Companyâs major product is Pexa-Vec, which is in a global Phase 3 clinical trial that is used for the treatment of liver cancer. Additionally, it also offers oncolytic virus immunotherapeutics, including SJ-102, SJ-103, SJ-815, JX-929, JX-930, JX-963, JX-970 and others.970 and others.
Calendar
2024-08-12
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -48.26% | 257M | |
| +16.61% | 121B | |
| +17.75% | 110B | |
| +17.23% | 25.98B | |
| -24.11% | 19.27B | |
| -18.56% | 15.99B | |
| -18.47% | 15.66B | |
| -47.75% | 14.5B | |
| +57.35% | 14.47B | |
| +5.62% | 13.91B |
- Stock Market
- Equities
- A215600 Stock
